GENFIT (GNFT)
(Delayed Data from NSDQ)
$4.84 USD
+0.65 (15.51%)
Updated Sep 20, 2024 03:59 PM ET
After-Market: $4.93 +0.09 (1.86%) 7:58 PM ET
2-Buy of 5 2
C Value F Growth A Momentum C VGM
Brokerage Reports
0 items in cart
GENFIT S.A. Unsponsored ADR [GNFT]
Reports for Purchase
Showing records 1 - 20 ( 118 total )
Company: GENFIT S.A. Unsponsored ADR
Industry: Medical - Biomedical and Genetics
We Expect EU Approval of Iqirvo in Late September; PoC Data From Lead ACLF Program Due in 2H24; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: GENFIT S.A. Unsponsored ADR
Industry: Medical - Biomedical and Genetics
IQIRVO Approved for 2L PBC; Partner Ipsen to Launch Immediately With Favorable Label; Raise PT to $13
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: GENFIT S.A. Unsponsored ADR
Industry: Medical - Biomedical and Genetics
EASL Presentation Highlight Elafibranor''s Extended Efficacy to Week-78
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: GENFIT S.A. Unsponsored ADR
Industry: Medical - Biomedical and Genetics
1Q Recap: Expecting a Busy 2024 With Three Elafibranor Regulatory Decisions; Cash Runway Extends Out to 4Q25; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: GENFIT S.A. Unsponsored ADR
Industry: Medical - Biomedical and Genetics
FY2023 Recap; Elafibranor Could Be Approved For Three Major PBC Markets in 2024
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: GENFIT S.A. Unsponsored ADR
Industry: Medical - Biomedical and Genetics
Three Regulatory Filings For Elafibranor in PBC Submitted; We Look For Progress Across ACLF Programs in 2024; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: GENFIT S.A. Unsponsored ADR
Industry: Medical - Biomedical and Genetics
1H23 Recap; First Elafibranor PBC Regulatory Filing Expected By Year-End 2023; Pipeline Expansion Continues; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: GENFIT S.A. Unsponsored ADR
Industry: Medical - Biomedical and Genetics
Positive ELATIVE Phase 3 Dataset Supports Elafibranor''s Potential U.S. Approval For PBC in 2H24; Increasing PT to $11
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: GENFIT S.A. Unsponsored ADR
Industry: Medical - Biomedical and Genetics
GENFIT Acquires Global Rights to ASK1 Inhibitor For ACLF; Phase 3 ELATIVE PBC Data Expected in June; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: GENFIT S.A. Unsponsored ADR
Industry: Medical - Biomedical and Genetics
Journal of Hepatology Highlights Potential of NIS2+ as NASH Diagnostic Tool in Clinical Trials; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: GENFIT S.A. Unsponsored ADR
Industry: Medical - Biomedical and Genetics
FY22 Recap; Top-line Phase 3 PBC Readout in June; Adding ACLF, CCA Programs to Model; Raise PT to $9; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: GENFIT S.A. Unsponsored ADR
Industry: Medical - Biomedical and Genetics
GNS561 Granted Orphan Drug Designation For HCC; Phase 3 ELATIVE Readout in 2Q23 Represents Key Catalyst; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: GENFIT S.A. Unsponsored ADR
Industry: Medical - Biomedical and Genetics
1H22 Recap; GENFIT''s Pipeline Now Has Six Programs; Phase 3 ELATIVE PBC Top-Line Data On Target in 2Q23; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: GENFIT S.A. Unsponsored ADR
Industry: Medical - Biomedical and Genetics
GENFIT Adds Two Key Assets to Its Liver Disease Pipeline With Versantis Acquisition; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: GENFIT S.A. Unsponsored ADR
Industry: Medical - Biomedical and Genetics
Healthcare Coverage Update - Dropping Coverage
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: GENFIT S.A. Unsponsored ADR
Industry: Medical - Biomedical and Genetics
2H21 Recap; ELATIVE Close to Complete Enrollment; Top-Line Readout on Target in 2Q23
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: GENFIT S.A. Unsponsored ADR
Industry: Medical - Biomedical and Genetics
GENFIT Signs Two Transformative Deals; Upgrading Our Rating to Buy With $8 PT on a Renewed Outlook
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: GENFIT S.A. Unsponsored ADR
Industry: Medical - Biomedical and Genetics
1H21 Recap; Phase 3 ELATIVE Timeline Slightly Delayed by COVID-19
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: GENFIT S.A. Unsponsored ADR
Industry: Medical - Biomedical and Genetics
FY20 Recap; GENFIT Continues Its Transition in 2021 As Phase 3 ELATIVE PBC Trial Continues; Maintain Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: GENFIT S.A. Unsponsored ADR
Industry: Medical - Biomedical and Genetics
YE20 Pro-Forma Cash Roughly $150M; Full Year 2020 Results Expected on April 1; Maintain Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E